gerresheimer

INDUSTRIALISATION OF PHARMACEUTICAL AND MEDICAL DEVICES IN THE SCIENTIFIC MOULDING APPROACH

Here, Thomas Rudolph, Global Team Lead, Process Engineering, Markus Reil, Head of Plant Quality & Global Quality Engineering, Stefan Schumann, Engineer Advanced Technology Moulds, and Tobias Weigert, Global Team Lead Metrology, all of Gerresheimer, discuss the company's strategy for managing potential risks across the entire product lifecycle, including the identification of all parameters within the injection moulding process using highly precise measurement technology.

There are very few other industrial sectors where reliable quality plays such a crucial role as in the drug delivery device sector. Every faulty product can put the efficacy of a therapy and, in extreme cases, the life and health of the patient at risk. With this in mind, Gerresheimer made a paradigm shift years ago (Figure 1). The goal of the company's quality strategy is no longer to weed out faulty products at the end of the production process (quality by inspection) but instead to design the entire product lifecycle around preventing faulty products in the first place (quality by design). In so doing, Gerresheimer reduces the risk of rejected batches, ensures interruptionfree product delivery for its customers and benefits patients, who can rely on flawless primary packaging and reliably functioning devices.

RISK-BASED APPROACH

A deciding factor for successful quality by design is to recognise all the relevant risks in the product lifecycle, classify them according to their severity and develop appropriate strategies for mastering them. By identifying, rating and prioritising these risks, Gerresheimer lays a reliable foundation for all stages of the product engineering process. This approach can be split into three pillars:

- 1. Risk management, in the form of targeted, prioritised management of risks performed as a continuous task
- 2. Control strategy in production, which ensures that the quality levels corresponding to the risks are met in series production over the long term
- 3. Validation strategy, which acts as the link between the other two pillars, accounting for the fact that long-term data from series production are, statistically, always worse than the short-term data from the validation phase.

By taking a risk-based quality approach, producer and consumer risk can be clearly limited. The customer's requirements for the product are translated into key figures, which enable precise measurement of the required properties. During the product

"By identifying, rating and prioritising these risks, Gerresheimer lays a reliable foundation for all stages of the product engineering process."

Thomas Rudolph

Global Team Lead, Process Engineering T: +49 9431 639 6973 E: thomas.rudolph@gerresheimer.com

Markus Reil

Head of Plant Quality & Global Quality Engineering T: +49 9431 639 7684 E: markus.reil@gerresheimer.com

Stefan Schumann

Engineer Advanced Technology Moulds T: +49 9431 639 77545 E: stefan.schumann@gerresheimer.com

Tobias Weigert

Global Team Lead Metrology T: +49 9431 639 6685 E: tobias.weigert@gerresheimer.com

Gerresheimer Regensburg GmbH Oskar-von-Miller-Str. 6 92442 Wackersdorf Germany

www.gerresheimer.com





Figure 1: Quality by design flowchart.

engineering phase, a strict validation strategy is defined based on the severity of the product risks determined in the linked failure modes and effects analyses and the acceptable business risks. In turn, the control strategy during production is determined by product risks and residual risks. The outcome is a production process where the customer can rely on product properties and quality without reservation.

Gx INNOSAFE – INTEGRATED PASSIVE SAFETY SYSTEM FOR PREVENTING NEEDLESTICK INJURIES

With their exposed cannulas, used syringes present an omnipresent source of danger in medical practices, laboratories and hospitals. Existing needle protection systems reduce the risk of injury for end users but require additional effort both during filling and when using the syringe. With Gx InnoSafe (Figure 2), Gerresheimer offers a syringe with an integrated passive safety system that is optimised for processes at pharmaceutical companies, preventing accidental needlestick injuries and reuse.

For users, injections are performed as usual. The syringe body is visible so users can check that it is filled and that the contents are pure, as well as optimally monitoring administration. After removal of the sealing cap with an integrated flexible needle shield, the syringe is placed at the site of injection, the cannula inserted into the tissue and the active agent injected. Accidental triggering of the safety system is ruled out as the mechanism is not activated until the cannula is inserted, and the safety mechanism is automatically and permanently locked once the syringe is removed from the site of injection. In this way, the cannula is reliably concealed and syringe reuse is prevented.

For the pharmaceutical company, the Gx InnoSafe offers all the benefits of the readyto-fill (RTF) syringe filling process. During production, the safety system is assembled on Gx RTF glass syringes in the cleanroom

> "Due to the impossibility of inline testing, quality assurance for the sealing mechanism must take place via statistically analysed samples."

just as with a standard needle shield. The syringes are packed with the safety system in a 100-hole nest and tub format, then sealed and sterilised with ethylene oxide. They can be processed on existing filling lines without additional preparation and assembly steps.

MEASUREMENT TECHNOLOGY – KEY COMPETENCE FOR THE SCIENTIFIC MOULDING APPROACH

Gx InnoSafe was developed to prevent needlestick injuries, which is one of the greatest residual risks for syringe-based injections. A quality level adequate for the risk plays a decisive role when it comes to success in clinical practice. However, this is anything but trivial when it comes to mass production of a product. While the whole range of quality criteria can be fully checked inline during production, this does not include the most critical function of Gx InnoSafe – the irreversible sealing of the needle.

Due to the impossibility of inline testing, quality assurance for the sealing mechanism must take place via statistically analysed samples. For the product, maximum reliable (worst-case) error rates were defined for series production based on the risk management severity. The testing strategy for series production was then determined based on the required sample sizes and acceptance criteria. For validation, the sample sizes and acceptance criteria were tightened, based on internal quality processes, to ensure that a quality level corresponding to the application risks is reached over the long term. Risk-based product reliability values exceeding 99% and a statistical confidence level of 95% were applied.

To achieve reproducible measurement results during function tests, measurement methods were developed and optimised for use in series production, then qualified in Gerresheimer's metrology and quality lab. The test and functional parameters defined by quality engineering in the component requirement specification (CRS) have to be measurable using jigs on co-ordinatemeasuring equipment. Gerresheimer relies on Zeiss Contura G2 and Zeiss O-Inspect CMMs (Carl Zeiss, Oberkochen, Germany) as standard for tactile and optical measurements to ensure department and location-independent reproducibility.

In parallel with mould making, a measurement strategy is developed and co-ordinated with the customer or quality



Figure 2: Gerresheimer's Gx InnoSafe safety system.



Figure 3: Virtual test programs are created in parallel for qualifying standard probes.

engineering. As a result, a measuring device can be derived, which is available for measuring the first test samples in Gerresheimer's Technical Competence Center in Wackersdorf. The creation of the test programs takes place virtually, in parallel, to ensure that the defined standard probes can be used. (Figure 3).

SCIENTIFIC MOULDING APPROACH

Quite a number of process variables define an injection moulding process and

must be considered when establishing a robust process for achieving consistent part quality. Application of a scientific moulding approach helps in understanding the characteristics of each parameter and its influence on a specific part. The goal is to analyse the whole injection moulding process, from the time the resin enters the injection moulding machine to when it leaves the mould as a finished part, with the ultimate aim of establishing a process that minimises variation in part quality.

"The goal is to analyse the whole injection moulding process, from the time the resin enters the injection moulding machine to when it leaves the mould as a finished part, with the ultimate aim of establishing a process that minimises variation in part quality." During the first step, the back pressure, suck back, cavity balance, injection rate via viscosity curve, holding time, switch over point, clamping force and cooling time parameters are analysed. Whenever it is possible, in-cavity pressure sensors are used to optimise the process.

This is followed by a parameter screening to determine an aesthetic process window within which visually acceptable parts can be produced. As standard procedure, the four parameters of melt temperature, mould temperature, injection speed and holding pressure are varied. This provides information about the performance and limitations of the mould, as the chosen variables are stretched to their limits to determine the inherent limits of the mould. The wider the limits are, the bigger the process window is and the more robust is the process. As the screening provides a window for visual appearance of the part, dimensional data must be taken afterwards.





Figure 4: Two MSAs are conducted as part of tool qualification.

Once the process parameter limits have been determined, a fraction factorial design of experiments (DoE) is performed to investigate main effects and parameter interactions on the most critical and functional dimensions, as defined in the CRS. DoE can be performed on serial machines or pilot plant injection moulding machines of various types and sizes, as well as from different manufacturers.

After the measuring jig has been produced and delivered by the in-house tool shop, it is then qualified with the test program. This means that a defined and co-ordinated qualification plan is used to ensure that production has taken place according to specifications. It also includes the successful completion of two measurement system analyses (MSAs). A CG value of >1.33 applies as the acceptance criterion for MSA 1 along with a gage R&R value of <20% for MSA 2 (Figure 4). This ensures that identical measurements are generated across all fixture positions and that the operator influence is kept to a minimum. After completing all qualification sections, the system is approved for tool qualification and can be used for all further measurements, including DoE, measurement report and process capability. As soon as the tool qualification is completed, the equipment is sent to the respective production site and used for in-process control.

Statistical analysis of the dimensional results of the DoE is then used to filter out the significant parameters for the considered dimensions and gives a deeper understanding of how the part behaviour depends on several parameter combinations (Figure 5). Based on the results of this analysis, either the mould steel will be adjusted to move dimensions to the centre of the process window or a parameter setting is chosen that already gives the best results regarding robustness.

Once the DoE analysis has revealed which combinations of parameters should be selected for a given tool, the components are measured according to the drawing. In addition, virtually all other dimensions defined on the drawing are measured using an X-ray scanner. At Gerresheimer, this is done on a Zeiss Metrotom 800, which scans and identifies the components based on a barcode as part of a fully automated process. Additionally, comprehensive test programs, which are programmed at the start of mould making, autonomously measure all the plastic components for each mould cavity. As a result, digital product data and measurement reports are available.

"The use of CT scans to fully measure plastic components is a key point and serves as a means of creating initial sample test reports at high speed and at a consistently high quality."



Figure 5: Interaction between process parameters.



Figure 6: X-ray data is used to show the difference between the measurements taken by different tools and deviations from the CAD model.

The use of computerised tomography (CT) scans to fully measure plastic components is a key point and serves as a means of creating initial sample test reports at high speed and at a consistently high quality. This is due to the fact that components can be measured without any possible warpage during clamping and in sequence ("one-shot measurement"). Gerresheimer also takes advantage of this when using jigs to measure test and functional dimensions.



Figure 7: Process capability report.

A comparison ensures that the measurement results from the X-ray scanner are comparable those of the jigs. The X-ray scanner makes it possible to show deviations from the computeraided design (CAD) model or between the results of different tools in false colours (Figure 6). The digitisation of the produced parts enables reverse engineering by comparing the component with the CAD model or 2D design drawings. Unlike with physical products, digitised products are not subjected to environmental factors or post-shrinkage. For example, this allows changes to the components since tool creation to be tracked precisely. Function or defect analyses of components and assemblies are made significantly easier by using CT scans.

In the course of industrialisation, the moulds go through optimisation loops and finally pass several qualification runs on the serial machine. When necessary, the process can be adapted through additional DoEs. Alternatively, adjustments can be made based on the in-cavity pressure curve in the mould evaluated on the pilot plant IMM as it contains all the necessary information on the flow of the molten plastic and solidification phases in the mould. Matching that fingerprint delivers parts with the same and consistent quality, as well as being machine independent.

Qualification runs on the serial machine are performed at low and high levels based on the nominal process setting. With these runs, the natural variation of the key process parameters can be considered,

UNPARALLELED TIGHT TOPIC FOCUS EVERY ISSUE FOR MORE THAN 130 ISSUES

www.ondrugdelivery.com/subscribe





allowing for a following analysis to confirm the process capability of the critical dimensions at the chosen limits. To perform a preliminary process capability analysis, at least 25 components of each cavity have to be measured. The Ppk value required by the customer serves as the acceptance criterion. A typical value for this kind of standard distribution with a confidence interval of $\pm 3s$ is 1.67. This means that the probability that components meeting the quality requirements are produced is 99.73% (Figure 7).

Besides the lab for dimensional measurement of components, assemblies and finished products, Gerresheimer also has a lab for function testing. It is equipped with a 4K digital microscope, a high-speed camera, a test station for metering accuracy, a 3D printer for rapid prototyping and three material test machines from Zwick Roell (Ulm, Germany), a six-axle robot and two climatic test chambers.

CONCLUSION

At Gerresheimer, quality is no longer ensured by sorting out faulty parts after production but is instead established systematically in the products and processes during the development and industrialisation phases. During all phases of product engineering, the quality assurance department works closely with all the other departments involved. In this way, quality by design is not only the safest but also the most efficient way to launch medical products on the market.

ABOUT THE COMPANY

With a wide range of products for pharmaceutical packaging and drug delivery devices, Gerresheimer is a global partner in the areas of pharmaceuticals, health, wellness and biotech. With locations in Europe, the US and Asia, Gerresheimer produces hundreds of millions of successful drug delivery systems and primary packaging components quickly, cost-efficiently and with a high standard of quality each year. In the area of drug delivery devices, Gerresheimer covers the entire range of drug delivery, from inhalers, through autoinjectors and pen injectors, to needle-free injection systems, all the way to classic injection systems. Just as comprehensive is Gerresheimer's service offering, which covers the entire value chain, from the initial idea to product development with in-house tooling and special machine engineering, to large-scale production, assembly and international distribution. Close collaboration with the customer results in products that safely and reliably deliver the customer's active agents to patients.

ABOUT THE AUTHORS



Thomas Rudolph holds a Dipl-Ing in Mechanical Engineering with a focus on plastics technology. He started at Gerresheimer's Technical Competence Center in Wackersdorf in 2005 and heads a global team of injection moulding process engineers. He and his team are responsible for developing robust injection moulding processes with the help of scientific methods and the transfer of qualified injection moulds to the global production sites.



Markus Reil studied machine engineering at the Amberg-Weiden University of Applied Science (Amburg, Germany) with a special focus on laser technology, graduating in 2003. Between 2003 and 2007, he worked in several positions to gather professional experience. In 2007 he took part in an in-house education programme at Gerresheimer's Technical Competence Center in Wackersdorf and received a certificate as "Six-Sigma Black Belt (Grundig Akademie)". In 2017 Reil was appointed as Head Plant Quality & Global Quality Engineering.



Stefan Schumann started a dual master's degree in plastics technology in combination with an apprenticeship as a Process Mechanic for plastics and rubber technology at Gerresheimer. From 2016 to 2017 he performed research in the field of innovation-focused mechanical engineering. After successfully completing his degree, he started as an Expert in Injection Moulding in the Mould Process Engineering department of Gerresheimer's Technical Competence Center in Wackersdorf. Since May 2021 he has been working as an Engineer in Advanced Technology Moulds in the Global Mould and Process Engineering department and is responsible for innovative technology projects in the area of mould development.



Tobias Weigert started his professional career with an apprenticeship as Mould Maker for jigs at Mühlbauer Group (Roding, Germany). In parallel with joining Gerresheimer in October 2013 as a Measurement Engineer, he completed his state certification in Mechanical Engineering. After that, he started his BA in Industrial Engineering, which he completed in 2019. Since 2018, Mr Weigert has led Gerresheimer's Global Metrology Team within Germany, the US and China for the Technical Competence Centers. Since the start of of 2021 he has also been part of the "Formula GT" programme, which is an internal Gerresheimer programme for employees with high potential.

We turn your vision single components and products ready-for-market



Customized Solutions

Gerresheimer – your international onestop-partner for drug delivery systems. Whether start-up or Fortune 500 company, we provide a service offering as individual as your active ingredient, patient or user.

Explore our services!

- Concept, product and process development
- Industrialization
- Contract Manufacturing



• 1

gerresheimer.com